Takeda Pharmaceutical Company Limited
時価総額
$59.0B
世界順位
#245
過去最高値
$62.6B
2026-07-29
総成長率
+0%
2026年以降
Market Cap Context
- Larger than 33% of the 367 companies we track (globally).
- Equivalent to 1.3% of Japan's GDP (2025 data).
- Just above: #244 Occidental Petroleum Corporation ($59.0B)
- Just below: #246 Fastenal Company ($58.8B)
- Best year: 2022 (+38%). Worst year: 2018 (-40%).
Takeda Pharmaceutical Company Limited Financial Breakdown (FY 2026)
Source: Yahoo Finance — 4502.T annual filings (2026) (converted from JPY at 152.0) →$29.6B revenue · $3.1B operating income · $-1.0B net income
- ●Operating margin: 10.3% on $29.6B in revenue.
- ●R&D is 15.0% of revenue ($4.4B).
- ●Net income margin: -3.4% — $-1.0B in profit.
- ●Free cash flow: $4.1B (13.9% of revenue).
Cost / Operating Expenses
Total operating expenses $26.6B
Total
$21.9B
Capital Expenditures
$2.7B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$4.1B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Takeda Pharmaceutical Company Limitedについて
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect".
Takeda Pharmaceutical Company Limitedの時価総額推移 (2026–2026)
Takeda Pharmaceutical Company Limited vs Sector Peers by Market Cap
Takeda Pharmaceutical Company Limitedを比較
順位の推移
| 年 | 時価総額 | 順位 | 前年比 |
|---|---|---|---|
| 2026 | $59.0B | #245(↑5) | +17.3% |
| 2025 | $50.3B | #250(↑8) | +20.9% |
| 2024 | $41.6B | #258(↑2) | +7.9% |
| 2023 | $38.6B | #260(↓30) | +2.7% |
| 2022 | $37.6B | #230(↑67) | +37.7% |
| 2021 | $27.3B | #297(↓46) | -12.5% |
| 2020 | $31.2B | #251(↓47) | -8.9% |
| 2019 | $34.2B | #204(↓7) | +22.0% |
| 2018 | $28.0B | #197(↓75) | -40.0% |
| 2017 | $46.8B | #122(↑12) | +36.7% |
| 2016 | $34.2B | #134(↓40) | -17.4% |
| 2015 | $41.4B | #94(↑21) | +25.2% |
| 2014 | $33.1B | #115(↓2) | +7.5% |
| 2013 | $30.8B | #113(↓4) | +29.8% |
| 2012 | $23.7B | #109 | +19.7% |
| 2011 | $19.8B | #109(↓9) | -11.3% |
| 2010 | $22.3B | #100(↓9) | +9.0% |
| 2009 | $20.5B | #91(↓34) | -13.4% |
| 2008 | $23.7B | #57(↑7) | -27.0% |
| 2007 | $32.5B | #64(↓22) | -18.0% |
| 2006 | $39.6B | #42(↑6) | +30.1% |
| 2005 | $30.4B | #48(↑7) | +25.7% |
| 2004 | $24.2B | #55(↑7) | +23.6% |
| 2003 | $19.6B | #62(↓25) | -13.0% |
| 2002 | $22.5B | #37(↑8) | -15.3% |
| 2001 | $26.6B | #45(↑6) | -11.5% |
| 2000 | $30.0B | #51 |
その他のヘルスケア企業
よくある質問
What is Takeda Pharmaceutical Company Limited's market cap?
Takeda Pharmaceutical Company Limited (4502.T) has a market capitalization of $59.0B, making it the #245 largest company in the world by market cap.
What was Takeda Pharmaceutical Company Limited's highest market cap?
Takeda Pharmaceutical Company Limited's all-time high market cap was $62.6B, reached in 2026-07-29. Its highest rank was #245 in 2026.
What sector is Takeda Pharmaceutical Company Limited in?
Takeda Pharmaceutical Company Limited is in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry. It is based in Japan.
How has Takeda Pharmaceutical Company Limited's market cap changed over time?
Takeda Pharmaceutical Company Limited has been tracked since 2026. Its market cap has grown by 0% from $59.0B in 2026 to $59.0B today.